A Phase IIa, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Nave, PD-L1 high metastatic NonSmall Cell Lung Cancer (NSCLC)

Trial Profile

A Phase IIa, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Nave, PD-L1 high metastatic NonSmall Cell Lung Cancer (NSCLC)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs AGEN 1884 (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Agenus
  • Most Recent Events

    • 22 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top